BCC-014-DFMO
Phase II
OPEN TO ACCRUAL
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
BCC-015
Phase II
OPEN TO ACCRUAL *
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
COG-AALL1821
Phase II
OPEN TO ACCRUAL
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC# 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
COG-AREN1921
Phase II
OPEN TO ACCRUAL *
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
PBMTC-ONC1401
Phase II
OPEN TO ACCRUAL
The Role of KIR-Favorably Mismatched Haploidentical Transplantation and KIR-Polymorphisms in Determining Outcomes of Children with ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation